LifeStance Q3 revenue $173.8M (+70% YoY); net loss $120.5M on stock comp; FY revenue guided to lower end of $668-678M

LifeStance Health Group, Inc.

Revenue $173.8M, up 70% YoY; Center Margin $52.1M (29.9% of revenue), up 57%.
Net loss $120.5M vs $3.3M loss a year ago, primarily driven by $120.7M stock/unit-based compensation.
Adjusted EBITDA $10.7M (6.2% of revenue), down 29% YoY from $15.0M.
Clinicians grew 72% to 4,375; added 400 net clinicians in Q3; retention stabilized ~80% annualized.
FY 2021 revenue expected toward lower end of $668-678M range; Center Margin and Adjusted EBITDA guidance unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.